Comparison of outcomes between single-port and multiport retroperitoneal robotic partial nephrectomy

May 11, 2025 by in ONCOLOGY Comments Off on Comparison of outcomes between single-port and multiport retroperitoneal robotic partial nephrectomy

Highlights • Single-port (SP) retroperitoneal robotic partial nephrectomy (RPN) is associated with a significantly longer ischemia time compared to the multiport (MP) approach, despite comparable perioperative and postoperative outcomes. •…

read more

Neoadjuvant chemotherapy before radical cystectomy in patients with organ-confined and non-organ-confined urothelial carcinoma

May 11, 2025 by in ONCOLOGY Comments Off on Neoadjuvant chemotherapy before radical cystectomy in patients with organ-confined and non-organ-confined urothelial carcinoma

Highlights • No population-based study validated the survival benefit of neoadjuvant chemotherapy recorded in clinical trials in a stage-specific fashion. • The current study represents the only retrospective analysis that…

read more

Analysis of risk factors for cancer-specific survival in neoadjuvant chemotherapy nonresponsive disease of muscle-invasive bladder cancer: A multicentre study from the Turkish Urooncology Association Bladder Tumor study group

May 11, 2025 by in ONCOLOGY Comments Off on Analysis of risk factors for cancer-specific survival in neoadjuvant chemotherapy nonresponsive disease of muscle-invasive bladder cancer: A multicentre study from the Turkish Urooncology Association Bladder Tumor study group

Highlights • Controversy remains regarding adjuvant therapy (AT) in patients treated with neoadjuvant chemotherapy (NAC) and radical cystectomy (RC) for muscle-invasive bladder cancer. • Determining variables that may affect cancer-specific…

read more

Radical cystectomy versus trimodal therapy for muscle-invasive bladder cancer: Analysis of an other-cause mortality matched cohort

May 11, 2025 by in ONCOLOGY Comments Off on Radical cystectomy versus trimodal therapy for muscle-invasive bladder cancer: Analysis of an other-cause mortality matched cohort

Highlights • In the absence of evidence from randomized controlled trials, Trimodal Therapy (TMT) for muscle-invasive bladder cancer (MIBC) is usually reserved to patients with poor overall health status. •…

read more

Radical cystectomy with stentless urinary diversion: A systematic review and meta-analysis of comparative studies

May 11, 2025 by in ONCOLOGY Comments Off on Radical cystectomy with stentless urinary diversion: A systematic review and meta-analysis of comparative studies

Highlights • Stented radical cystectomies had higher major complications ( P = 0.04); • Stentless radical cystectomy was noninferior in UIAS rate; • Stentless radical cystectomy was noninferior in UIAL rate;…

read more

Controversies in prostate cancer screening

May 11, 2025 by in ONCOLOGY Comments Off on Controversies in prostate cancer screening

Abstract Prostate cancer is the second most diagnosed cancer and the fifth leading cause of cancer death among men worldwide. In the 1980s, the development and implementation of Prostate-Specific Antigen…

read more

Prostate-specific antigen screening for prostate cancer: Diagnostic performance, clinical thresholds, and strategies for refinement

May 11, 2025 by in ONCOLOGY Comments Off on Prostate-specific antigen screening for prostate cancer: Diagnostic performance, clinical thresholds, and strategies for refinement

Abstract Prostate specific antigen (PSA) has transformed the diagnosis and treatment of prostate cancer by enabling early detection at global scale. Due to expression in both benign and malignant cells,…

read more

A systematic review of family history, race/ethnicity, and genetic risk on prostate cancer detection and outcomes: Considerations in PSA-based screening

May 11, 2025 by in ONCOLOGY Comments Off on A systematic review of family history, race/ethnicity, and genetic risk on prostate cancer detection and outcomes: Considerations in PSA-based screening

Highlights • Family history of prostate cancer is an important risk factor of being diagnosed with the disease, even in the setting of low PSA. • Black men are at…

read more

Randomized trials of PSA screening

May 11, 2025 by in ONCOLOGY Comments Off on Randomized trials of PSA screening

Highlights • Randomized trials show PSA screening decreases prostate cancer-mortality. • Adjunct tests and focus on high-risk patients will improve prostate cancer screening. • A closer look at divergence in…

read more
Get Clinical Tree app for offline access